Hjem › Myelofibrose › Maryland
Myelofibrose kliniske forsøg i Maryland
9 studier for Myelofibrose søger deltagere på steder i Maryland.
Byer i Maryland
Officiel studietekst (engelsk)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Maryland, Baltimore
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07357727Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RekruttererTidlig fase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06398457A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Johns Hopkins University, Baltimore
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- John Hopkins Hospital, Baltimore
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Johns Hopkins Hospital, Baltimore
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 17. apr. 2026 · NCT06034002A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 12. feb. 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- og 1 flere
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT06479135Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.